For COVID-19 patients with diabetes, insulin therapy has been associated with increased mortality (41, 42), whereas metformin initially exhibited a therapeutic potential during the early stage of the pandemic (43, 44), possibly due to its antiviral and anti-inflammatory properties (44, 45). The gene discussed is INS; the disease is COVID-19.